Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of the Safety and Efficacy of Allovectin-7® Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

NCT00050388 is registered in ClinicalTrials.gov with Vical as lead sponsor.

NCT NCT00050388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00050388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of the Safety and Efficacy of Allovectin-7® Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Lead sponsor
Vical
Phase
Phase 3
Overall status
Completed
Start date
Not reported
Completion date
June 30, 2002
Enrollment
Not reported
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma of the head and neck, head and neck cancer, head and neck neoplasms, squamous cell carcinoma of the oral cavity or oropharynx